Trial Profile
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb IschemiaRutherford 5
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders; Ulcer
- Focus Registrational; Therapeutic Use
- Acronyms HOPE CLTI-2; Rutherford 5
- Sponsors Beijing Northland Biotech
- 12 Aug 2022 Trial design and rationale from tow clinical trials (HOPE CLTI-1 and HOPE CLTI-2) published in the American Heart Journal
- 29 Mar 2022 Planned End Date changed from 6 Mar 2022 to 31 Dec 2023.
- 29 Mar 2022 Planned primary completion date changed from 16 Jul 2021 to 31 Oct 2023.